A Japan­ese flu drug gets up­beat re­views in Chi­na for blunt­ing the im­pact of Covid-19 — and that is bol­ster­ing Gilead­'s case for remde­sivir

We’re start­ing to get the first round of da­ta on drugs be­ing used to rein in the dev­as­tat­ing out­break of Covid-19 in Chi­na. And one drug from Japan is get­ting a thumbs-up based on a pair of small tri­als be­ing used as piv­otals in the cri­sis — which ap­pear to open the way to wide­spread use.

That new read­out has al­ready at­tract­ed the at­ten­tion of one Wall Street an­a­lyst, who sees a di­rect read-through to Gilead’s remde­sivir, where da­ta on the coro­n­avirus are ex­pect­ed in weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER